Related Experiment Videos
Pneumococcal infection and immunization in children
1Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892.
Insights
Pneumococcal conjugate vaccines with inactivated pneumolysin show promise for protecting young children. Enhancing vaccine immunogenicity is key to preventing serious pneumococcal diseases in vulnerable populations.
Area of Science:
- Immunology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Pneumococcal infections cause significant pediatric diseases like meningitis, pneumonia, and bacteremia.
- Young children under two years old are most susceptible to severe pneumococcal infections.
- Specific pneumococcal serotypes are responsible for the majority of pediatric disease cases.
Purpose of the Study:
- To evaluate the protective immunity conferred by pneumococcal polysaccharide (PS)-protein conjugates containing inactivated pneumolysin in young mice.
- To investigate the impact of PS molecular size on antibody response in conjugate vaccines.
- To explore strategies for enhancing the immunogenicity of pneumococcal vaccines for young children.
Main Methods:
- Young mice were immunized with pneumococcal type 9V PS conjugated to inactivated pneumolysin.
- Bacterial clearance and antibody responses were assessed post-immunization.
- The effect of molecular size of pneumococcal type 19F PS in conjugate preparation on antibody response was examined.
Main Results:
- Pneumococcal PS-protein conjugate vaccination conferred protective immunity against pneumococcal infection in young mice.
- Inactivated pneumolysin as a PS-protein conjugate enhanced vaccine efficacy.
- Conjugates prepared with larger molecular weight 19F PS elicited a higher antibody response.
Conclusions:
- Pneumococcal PS-protein conjugate vaccines, potentially including inactivated pneumolysin, can induce protective immunity.
- The molecular size of PS is critical for achieving a robust antibody response in conjugate vaccines.
- Developing improved conjugate vaccines is essential to overcome the poor immunogenicity of traditional pneumococcal vaccines in infants.
Abstract:
Pneumococcal infection persists as a major cause of pneumonia, bacteremia, and otitis media and is the important cause of meningitis in young children. Children less than 2 years of age show the highest incidence of pneumococcal diseases. Pneumococcal types 6A + 6B, 7F, 9V, 14, 18C, 19F + 19A, and 23F account for the large majority of disease isolates in the pediatric population. Bacterial clearance and antibody response were studied in young mice from mothers injected with pneumococcal type 9V polysaccharide (PS) conjugated with the inactivated pneumolysin to examine the protective immunity of young mice to pneumococcal infection. The injection of mice with pneumococcal PS-protein conjugate conferred the protective immunity to pneumococcal infection. The efficacy of pneumococcal vaccine might be enhanced by addition of inactivated pneumolysin in the form of PS-protein conjugate. The molecular size of pneumococcal type 19F PS or oligosaccharide used for preparing the PS-protein conjugate has a profound effect on the antibody response to the PS. The conjugate immunogen prepared from a large molecule of 19F PS produced a high antibody response to the PS in young mice. Development of a PS-protein conjugate vaccine for selected pneumococcal types will help in solving problems of poor immunogenicity of pneumococcal PS vaccine in young children.